Andrew P. Han

The firm is also bringing its comprehensive genomic profiling assay for cancer to the Ion Torrent Genexus sequencing platform in the first half of 2023.

Labs should not let in silico data supplant physical specimens in bioinformatic validation and should understand the limitations of such data.

Separately, the US Federal Trade Commission said it will appeal an administrative law judge's initial decision in an antitrust case that was favorable to Illumina.

According to the firm, the judge "rejected the FTC's position that the deal would adversely affect competition" of multi-cancer early detection tests.

Critics of the bill suggested that it would allow patents on pathogen genetic material, which could hamper the ability to test and treat in future pandemics.

Though the funding is technically there, doctors may not be comfortable ordering the test and hospitals may wonder if they'll lose money from it.

The firm also spoke about the need to interact with the FDA to clarify how to get its SomaSignal assay for cardiovascular events into clinical trials.

By the end of the year, SomaLogic plans to add 10 more SomaScan diagnostic assays, CEO Roy Smythe told investors, bringing the total to around 30 assays.

Both suits referenced a recent story in the New York Times about poor NIPT performance for rarer chromosomal abnormalities, especially microdeletions.

Illumina is seeing continued strength in its core next-generation sequencing business as the firm is officially bringing Grail on board.